Although Tris DBA has been demonstrated to inhibit STAT3 signaling and induce cytotoxicity in cancer cell lines in an in vivo model, previous studies have shown that Tris DBA can also regulate the activity of many cancer-related proteins (such as MAPK, Akt, STAT3, phospho-S6 kinase, and N-myristoyltransferase-1). The gene discussed is STAT3; the disease is cancer.